"10.1371_journal.pone.0024308","plos one","2011-09-01T00:00:00Z","Melvin M Evers; Barry A Pepers; Judith C T van Deutekom; Susan A M Mulders; Johan T den Dunnen; Annemieke Aartsma-Rus; Gert-Jan B van Ommen; Willeke M C van Roon-Mom","Center for Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands; Prosensa Therapeutics B.V., Leiden, The Netherlands; Leiden Genome Technology Center, Leiden University Medical Center, Leiden, The Netherlands","Conceived and designed the experiments: MME BAP JCTD SAMM JTDD AAR GJBO WMCRM. Performed the experiments: MME BAP. Analyzed the data: MME WMCRM. Contributed reagents/materials/analysis tools: JCTD SAMM. Wrote the paper: MME WMCRM.","Judith C.T. van Deutekom and Susan A.M. Mulders report being employed by Prosensa BV. Prosensa BV holds a patent on the use of AONs to reduce CAG and GTG repeat containing transcripts and may (ultimately) benefit from the application of the submitted information. The LUMC does not have any patents on the reported area and has no financial relationship with Prosensa in the field of triplet expansion diseases, nor foresees to benefit otherwise from the use of the reported information. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.","2011","09","Melvin M Evers","MME",8,TRUE,8,2,2,2,TRUE,TRUE,FALSE,0,NA,FALSE
